Evaluation of the Effect of Epitomee Device on Gastric Emptying Rate in Healthy Subjects

The participants will be enrolled in one investigational site. Subjects meeting eligibility criteria will undergo a gastric emptying test using gastric scintigraphy before any treatment (baseline).

Following the scintigraphy, the subjects will receive Tulip Device treatment - 2 capsules/day.

After repeated capsule intake for either 4 or 11 or 28 days, the subjects will undergo additional gastric emptying test with a capsule intake prior to the test meal.

Inclusion criteria

• 21 ≤ Age <65 years
• 20 < BMI ≤ 40 kg/m2
• Healthy subject
• Subject is able and willing to give informed consent
• Subject is able and willing to participate in the study and follow protocol procedures

Exclusion criteria

• Significant swallowing disorders or difficulty swallowing
• Suspected GI strictures, fistulas or other GI track obstructions
• Crohn's disease or diverticulosis
• Recent GI surgery
• History of long-standing undigested food in the stomach
• Known ulcer disease
• Organic disease associated with gastroparesis such a Parkinson's disease, cerebrovascular accident, neuromuscular disease or eating disorder
• Presence of a gastrostomy tube or gastric outlet obstruction
• History or evidence of any active liver disease
• Allergy to eggs
• Treatment with anticholinergic or prokinetic agents
• Treatment with proton-pump inhibitors
• Hypothyroidism, hyperthyroidism or taking thyroid hormone deficiency drugs (such as L-thyroxine)
• Prediabetes or Diabetes
• Any history or evidence of significant cardiac, renal, neurologic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease or symptom which in the judgment of the investigator would interfere with the study or confound the results
• Pregnancy or breastfeeding
• Currently participating in an ongoing clinical study